Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. Dermatol Online J 2014 Jan 15;20(1):21242
Date
01/25/2014Pubmed ID
24456946Scopus ID
2-s2.0-84892704051 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
BACKGROUND: Imatinib mesylate is a selective tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia. Ocular side effects of imatinib include periorbital edema, which may become so severe as to obstruct the visual field.
PURPOSE: The purpose of this case study is to describe the clinical characteristics of imatinib- induced postoperative periorbital purpura.
MATERIALS AND METHODS: We retrospectively reviewed the medical literature using PubMed, searching the terms edema, Gleevec, imatinib, periorbital, postoperative and purpura. Patient reports and previous reviews of the subject were critically assessed and the salient features are presented.
RESULTS: Three patients have undergone surgery to reduce the imatinib-induced periorbital edema; two of these individuals have developed imatinib-induced postoperative periorbital purpura.
CONCLUSION: We recommend discontinuing imatinib usage one week prior to periorbital surgery and not resuming therapy until the eighth postoperative day.
Author List
Anzalone CL, Cohen PR, Kurzrock R, Cortes JEAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAntineoplastic Agents
Benzamides
Blepharoplasty
Drug Administration Schedule
Ecchymosis
Edema
Eyelid Diseases
Female
Humans
Hyperpigmentation
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
Piperazines
Postoperative Complications
Postoperative Hemorrhage
Preoperative Care
Protein Kinase Inhibitors
Purpura
Pyrimidines
Retrospective Studies
Skin Transplantation
